|
1
|
Fang F, Balch C, Schilder J, Breen T,
Zhang S, Shen C, Li L, Kulesavage C, Snyder AJ, Nephew KP and Matei
DE: A phase 1 and pharmacodynamic study of decitabine in
combination with carboplatin in patients with recurrent,
platinum-resistant, epithelial ovarian cancer. Cancer.
116:4043–4053. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bast RC Jr, Hennessy B and Mills GB: The
biology of ovarian cancer: New opportunities for translation. Nat
Rev Cancer. 9:415–428. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pchejetski D, Alfraidi A, Sacco K,
Alshaker H, Muhammad A and Monzon L: Histone deacetylases as new
therapy targets for platinum-resistant epithelial ovarian cancer. J
Cancer Res Clin Oncol. 142:1659–1671. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ma X, Ezzeldin HH and Diasio RB: Histone
deacetylase inhibitors: Current status and overview of recent
clinical trials. Drugs. 69:1911–1934. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wagner JM, Hackanson B, Lubbert M and Jung
M: Histone deacetylase (HDAC) inhibitors in recent clinical trials
for cancer therapy. Clin Epigenetics. 1:117–136. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Miller CP, Singh MM, Rivera-Del Valle N,
Manton CA and Chandra J: Therapeutic strategies to enhance the
anticancer efficacy of histone deacetylase inhibitors. J Biomed
Biotechnol. 2011:5142612011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhu K, Qu D, Sakamoto T, Fukasawa I,
Hayashi M and Inaba N: Telomerase expression and cell proliferation
in ovarian cancer cells induced by histone deacetylase inhibitors.
Arch Gynecol Obstet. 277:15–19. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shahshahan MA, Beckley MN and Jazirehi AR:
Potential usage of proteasome inhibitor bortezomib (Velcade,
PS-341) in the treatment of metastatic melanoma: Basic and clinical
aspects. Am J Cancer Res. 1:913–924. 2011.PubMed/NCBI
|
|
9
|
Moody CA and Laimins LA: Human
papillomavirus oncoproteins: Pathways to transformation. Nat Rev
Cancer. 10:550–560. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Russo A, Fratto ME, Bazan V, Schiro V,
Agnese V, Cicero G, Vincenzi B, Tonini G and Santini D: Targeting
apoptosis in solid tumors: The role of bortezomib from preclinical
to clinical evidence. Expert Opin Ther Targets. 11:1571–1586. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kao C, Chao A, Tsai CL, Lin CY, Chuang WC,
Chen HW, Yen TC, Wang TH, Lai CH and Wang HS: Phosphorylation of
signal transducer and activator of transcription 1 reduces
bortezomib-mediated apoptosis in cancer cells. Cell Death Dis.
4:e5122013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Santo L, Hideshima T, Kung AL, Tseng JC,
Tamang D, Yang M, Jarpe M, van Duzer JH, Mazitschek R, Ogier WC, et
al: Preclinical activity, pharmacodynamic, and pharmacokinetic
properties of a selective HDAC6 inhibitor, ACY-1215, in combination
with bortezomib in multiple myeloma. Blood. 119:2579–2589. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Friday BB, Anderson SK, Buckner J, Yu C,
Giannini C, Geoffroy F, Schwerkoske J, Mazurczak M, Gross H, Pajon
E, et al: Phase II trial of vorinostat in combination with
bortezomib in recurrent glioblastoma: A north central cancer
treatment group study. Neuro Oncol. 14:215–221. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sato A and Asano T, Ito K, Sumitomo M and
Asano T: Suberoylanilide hydroxamic acid (SAHA) combined with
bortezomib inhibits renal cancer growth by enhancing histone
acetylation and protein ubiquitination synergistically. BJU Int.
109:1258–1268. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Spratlin JL, Pitts TM, Kulikowski GN,
Morelli MP, Tentler JJ, Serkova NJ and Eckhardt SG: Synergistic
activity of histone deacetylase and proteasome inhibition against
pancreatic and hepatocellular cancer cell lines. Anticancer Res.
31:1093–1103. 2011.PubMed/NCBI
|
|
16
|
Kim J, Guan J, Chang I, Chen X, Han D and
Wang CY: PS-341 and histone deacetylase inhibitor synergistically
induce apoptosis in head and neck squamous cell carcinoma cells.
Mol Cancer Ther. 9:1977–1984. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Franken NA, Rodermond HM, Stap J, Haveman
J and van Bree C: Clonogenic assay of cells in vitro. Nature
Protoc. 1:2315–2319. 2006. View Article : Google Scholar
|
|
18
|
Schägger H: Tricine-SDS-PAGE. Nat Protoc.
1:16–22. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bhatt S, Ashlock BM, Toomey NL, Diaz LA,
Mesri EA, Lossos IS and Ramos JC: Efficacious proteasome/HDAC
inhibitor combination therapy for primary effusion lymphoma. J Clin
Invest. 123:2616–2628. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hui KF, Lam BH, Ho DN, Tsao SW and Chiang
AK: Bortezomib and SAHA synergistically induce ROS-driven
caspase-dependent apoptosis of nasopharyngeal carcinoma and block
replication of Epstein-Barr virus. Mol Cancer Ther. 12:747–758.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Karthik S, Sankar R, Varunkumar K and
Ravikumar V: Romidepsin induces cell cycle arrest, apoptosis,
histone hyperacetylation and reduces matrix metalloproteinases 2
and 9 expression in bortezomib sensitized non-small cell lung
cancer cells. Biomed Pharmacother. 68:327–334. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Steg AD, Burke MR, Amm HM, Katre AA,
Dobbin ZC, Jeong DH and Landen CN: Proteasome inhibition reverses
hedgehog inhibitor and taxane resistance in ovarian cancer.
Oncotarget. 5:7065–7080. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Russell P, Hennessy BT, Li J, Carey MS,
Bast RC, Freeman T and Venkitaraman AR: Cyclin G1 regulates the
outcome of taxane-induced mitotic checkpoint arrest. Oncogene.
31:2450–2460. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Androic I, Kramer A, Yan R, Rödel F, Gätje
R, Kaufmann M, Strebhardt K and Yuan J: Targeting cyclin B1
inhibits proliferation and sensitizes breast cancer cells to taxol.
BMC Cancer. 8:3912008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Soria JC, Jang SJ, Khuri FR, Hassan K, Liu
D, Hong WK and Mao L: Overexpression of cyclin B1 in early-stage
non-small cell lung cancer and its clinical implication. Cancer
Res. 60:4000–4004. 2000.PubMed/NCBI
|
|
26
|
Suzuki T, Urano T, Miki Y, Moriya T,
Akahira J, Ishida T, Horie K, Inoue S and Sasano H: Nuclear cyclin
B1 in human breast carcinoma as a potent prognostic factor. Cancer
Sci. 98:644–651. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Weng L, Du J, Zhou Q, Cheng B, Li J, Zhang
D and Ling C: Identification of cyclin B1 and Sec62 as biomarkers
for recurrence in patients with HBV-related hepatocellular
carcinoma after surgical resection. Mol Cancer. 11:392012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
He Y, Zhou Z, Hofstetter WL, Zhou Y, Hu W,
Guo C, Wang L, Guo W, Pataer A, Correa AM, et al: Aberrant
expression of proteins involved in signal transduction and DNA
repair pathways in lung cancer and their association with clinical
parameters. PLoS One. 7:e310872012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cloos CR, Daniels DH, Kalen A, Matthews K,
Du J, Goswami PC and Cullen JJ: Mitochondrial DNA depletion induces
radioresistance by suppressing G2 checkpoint activation in human
pancreatic cancer cells. Radiat Res. 171:581–587. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Stewart DJ: Tumor and host factors that
may limit efficacy of chemotherapy in non-small cell and small cell
lung cancer. Crit Rev Oncol Hematol. 75:173–234. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Huang HC, Shi J, Orth JD and Mitchison TJ:
Evidence that mitotic exit is a better cancer therapeutic target
than spindle assembly. Cancer Cell. 16:347–358. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kavallaris M: Microtubules and resistance
to tubulin-binding agents. Nat Rev Cancer. 10:194–204. 2010.
View Article : Google Scholar : PubMed/NCBI
|
